Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

Core Insights - Caribou Biosciences, Inc. is hosting a panel discussion on vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, aimed at expanding patient access for second-line large B cell lymphoma treatment [1][2] Company Overview - Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [6] - The company is advancing vispacabtagene regedleucel (vispa-cel), which is the first allogeneic CAR-T cell therapy in clinical trials with a PD-1 knockout designed to enhance CAR-T cell activity [4] Clinical Trial Information - The ANTLER phase 1 clinical trial is evaluating vispa-cel in adult patients with relapsed or refractory B cell non-Hodgkin lymphoma, with 84 patients treated as of September 2, 2025 [5] - The trial has shown positive data indicating that vispa-cel's efficacy and durability are comparable to autologous CAR-T cell therapies [5] Event Details - The expert panel discussion will take place in-person at the Hyatt Regency Orlando on December 6, 2025, and will also be available virtually [2][3] - The event will be moderated by Caribou's Chief Medical Officer, Dr. Tina Albertson, and will feature insights from leading physicians regarding access challenges and patient needs [2]